lunes, 19 de octubre de 2015

IFFS - additional comment on press releases from ASRM fertility conference‏


The American Society for Reproductive Medicine has issued press releases from their ongoing conference in Baltimore. The International Federation of Fertility Societies (IFFS) is issuing the following comments, which may be used in any press coverage of this work. These comments are embargoed to match the embargo on the original press releases.

(1)   Press release, “The Quebec experience..”

Professor Richard Kennedy (Coventry, UK), President Elect of the International Federation of Fertility Societies, said:

“This is good work. The most important single complication of assisted reproduction is multiple births, and multiple births tend to risk complications for mother and children. This work shows how a publicly funded model, working in tandem with strict guidelines on single embryo transfer (SET) can produce a win-win situation, in terms of access, success and better overall outcomes”.


(2)   Press release, “Health Outcomes for Fertile and Sub-Fertile Mothers and Their Offspring

Professor Richard Kennedy (Coventry, UK), President Elect of the International Federation of Fertility Societies, said:

“This work provides additional reassurance that the observed slight increase in birth defects following Assisted Reproduction seems to be a result of the underlying infertility problem, and not the as a result of the treatment”.

(3)   Press release, “Adult Stem Cells Restore Function to ovaries damaged by Chemotherapy”

Dr Edgar Mocanu (Dublin), Treasurer of the International Federation of Fertility Societies, said:

“Millions of women receive chemotherapy treatment yearly.  While cancer survival rates have increased dramatically, to date no effective method of preventing infertility after chemotherapy.

This first experimental study in mice, using human stem cells, holds great promise and proof in human models is eagerly awaited.  The potential applications include treatment of premature ovarian failure, restoration of hormonal and reproductive function after sterilising chemotherapy.  It could also open new avenues for the treatment of menopause induced health issues.

While controlled trials must confirm short and long term safety this proof of principle holds significant promise for women of all ages”.